{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:52:03Z","timestamp":1782215523571,"version":"3.54.5"},"reference-count":32,"publisher":"Termedia Sp. z.o.o.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pol J Pathol"],"abstract":"<jats:p>Splenic rupture is a\u00a0critical surgical condition that poses an immediate threat to the\u00a0patient\u2019s life. In most cases, mechanical trauma to the\u00a0organ results in the\u00a0rupture of\u00a0the\u00a0capsule, leading to\u00a0hemorrhage into the\u00a0peritoneal cavity. Spontaneous (pathological) spleen rupture (SPSR) is\u00a0considered when the\u00a0etiology of\u00a0the\u00a0rupture is non-traumatic. Spontaneous (pathological) spleen rupture is most commonly associated with hematological malignancies, though it remains a\u00a0rare condition. Only 8 cases have been caused by mantle cell lymphoma (MCL). This review presents the\u00a0case of\u00a0a\u00a059-year-old male patient who was treated with emergency splenectomy due to SPSR. Histopathological examination revealed MCL.<\/jats:p>","DOI":"10.5114\/pjp.2025.156558","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:56:51Z","timestamp":1765807011000},"page":"261-266","source":"Crossref","is-referenced-by-count":0,"title":["Spontaneous pathological splenic rupture as a\u00a0first manifestation of\u00a0mantle cell lymphoma \u2013 a\u00a0case report and literature review"],"prefix":"10.5114","volume":"76","author":[{"given":"Antoni","family":"Knera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Ciesielski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Placek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Kruszy\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"So\u0142ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Strzelczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Durczy\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Klimczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Hogendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"ref-1687892","doi-asserted-by":"crossref","unstructured":"Giagounidis AA, Burk M, Meckenstock G, Koch AJ,\u00a0Schnei- der W. Pathologic rupture of\u00a0the\u00a0spleen in hematologic malignancies: two additional cases. Ann Hematol 1996; 73:  297-302.","DOI":"10.1007\/s002770050245"},{"key":"ref-1687893","doi-asserted-by":"crossref","unstructured":"Williams J, Chiruka S. Spontaneous splenic rupture and rituximab-induced acute thrombocytopenia in a\u00a0patient with high-risk mantle cell lymphoma. Case Rep Haematol 2019; 2019: 2429098.","DOI":"10.1155\/2019\/2429098"},{"key":"ref-1687894","doi-asserted-by":"crossref","unstructured":"Lunning MA, Stetler-Stevenson M, Silberstein PT, Zenger V,\u00a0Marti GE. Spontaneous (pathological) splenic rupture in a\u00a0blastic variant of\u00a0mantle cell lymphoma: a\u00a0case report and\u00a0literature review. Clin Lymphoma 2002; 3: 117-120.","DOI":"10.3816\/CLM.2002.n.018"},{"key":"ref-1687895","doi-asserted-by":"crossref","unstructured":"American Society of\u00a0Haematology. A\u00a0clinical evaluation of\u00a0the\u00a0International Lymphoma Study Group classification of\u00a0non-Hodgkin\u2019s lymphoma. The\u00a0Non-Hodgkin\u2019s Lymphoma Classification Project. Blood 1997; 89: 3909-3918.","DOI":"10.1182\/blood.V89.11.3909"},{"key":"ref-1687896","unstructured":"Szymczyk M. Ch\u0142oniak z\u00a0kom\u00f3rek p\u0142aszcza. In: Walewski J. Nowotwory uk\u0142adu ch\u0142onnego. Centrum Medyczne Kszta\u0142cenia Podyplomowego, Warszawa 2011."},{"key":"ref-1687897","doi-asserted-by":"crossref","unstructured":"Jares P, Colomer D, Campo E. Molecular pathogenesis of\u00a0mantle cell lymphoma. J Clin Invest 2012; 122: 3416-3423.","DOI":"10.1172\/JCI61272"},{"key":"ref-1687898","doi-asserted-by":"crossref","unstructured":"Navarro A, Bea S, Pedro J, Campo E. Molecular pathogenesis of\u00a0mantle cell lymphoma. Hematol Oncol Clin N Am 2020; 34: 795-807.","DOI":"10.1016\/j.hoc.2020.05.002"},{"key":"ref-1687899","unstructured":"Teras LR, DeSantis CE, Cerhan JR, Morton LM,\u00a0Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by\u00a0World Health Organisation subtypes. CA Cancer J Clin 2016; 66: 443-459."},{"key":"ref-1687900","doi-asserted-by":"crossref","unstructured":"Zhou Y, Wang H, Fang W, Romaguer JE,\u00a0Zhang Y,\u00a0Delasalle KB, et al. Incidence trends of\u00a0mantle cell lymphoma in\u00a0United States between 1992 and 2004. Cancer 2008; 113: 791-798.","DOI":"10.1002\/cncr.23608"},{"key":"ref-1687901","unstructured":"SEER Cancer Stat Facts: non-Hodgkin lymphoma. National Cancer Institute. Bethesda, MD. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html (accesed: 09.09.2024)."},{"key":"ref-1687902","doi-asserted-by":"crossref","unstructured":"Pittaluga S, Verhoef G, Criel A, Maes A,\u00a0Nuyts J,\u00a0Boogaerts M, et al. Prognostic significance of\u00a0bone marrow trephine and peripheral blood smears in 55 patients with mantle cell lymphoma. Leuk Lymphoma 1996; 21: 115-125.","DOI":"10.3109\/10428199609067588"},{"key":"ref-1687903","doi-asserted-by":"crossref","unstructured":"Perry DA, Bast MA, Armitage JO,  Weisenburger DD. Diffuse intermediate lymphocytic lymphoma. A\u00a0clinicopathologic study and comparison with small lymphocytic lymphoma and diffuse small cleaved cell lymphoma. Cancer 1990; 66: 1995-2000.","DOI":"10.1002\/1097-0142(19901101)66:9<1995::AID-CNCR2820660925>3.0.CO;2-Q"},{"key":"ref-1687904","doi-asserted-by":"crossref","unstructured":"Jaffe ES, Bookman MA, Longo DL. Lymphocytic lymphoma of\u00a0intermediate differentiation-- mantle zone lymphoma: a\u00a0distinct subtype of\u00a0B-cell lymphoma. Hum Pathol 1987; 18: 877-880.","DOI":"10.1016\/S0046-8177(87)80262-9"},{"key":"ref-1687905","doi-asserted-by":"crossref","unstructured":"De Oliveira MS, Jaffe ES, Catovsky D. Leukaemic phase of\u00a0mantle zone (intermediate) lymphoma: its characterisation in 11 cases. J Clin Pathol 1989; 42: 962-972.","DOI":"10.1136\/jcp.42.9.962"},{"key":"ref-1687906","unstructured":"Vadlamudi G, Lionetti KA, Greenberg S, Mehta K. Leukemic phase of\u00a0mantle cell lymphoma two case reports and review of\u00a0the\u00a0literature. Arch Pathol LAb Med 1996; 120: 35-40."},{"key":"ref-1687907","doi-asserted-by":"crossref","unstructured":"Duggan MJ, Weisenburger DD, Ye YL, Bast MA,\u00a0Pierson JL, Linder J, et al. Mantle zone lymphoma. A\u00a0clinicopathologic study of\u00a022 cases. Cancer 1990; 66: 522-529.","DOI":"10.1002\/1097-0142(19900801)66:3<522::AID-CNCR2820660320>3.0.CO;2-4"},{"key":"ref-1687908","doi-asserted-by":"crossref","unstructured":"Norton AJ, Matthews J, Pappa V, Shamash J,\u00a0Love S,\u00a0Rohatiner AZ, et al. Mantle cell lymphoma: natural history defined in\u00a0aserially biopsied population over a\u00a020-year period. Ann Oncol 1995; 6: 249-256.","DOI":"10.1093\/oxfordjournals.annonc.a059154"},{"key":"ref-1687909","doi-asserted-by":"crossref","unstructured":"Harris NL, Jaffe ES, Stein H, Banks PM,\u00a0Chan JK,\u00a0Cleary ML, et al. A\u00a0revised European-American classification of\u00a0lymphoid neoplasms: a\u00a0proposal from the\u00a0International Lymphoma Study Group. Blood 1994; 84: 1361-1392.","DOI":"10.1182\/blood.V84.5.1361.bloodjournal8451361"},{"key":"ref-1687910","doi-asserted-by":"crossref","unstructured":"Xu J, Medeiros LJ, Saksena A, Wang M,\u00a0Zhou J,\u00a0Li J, et al. CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of\u00a030 cases. Oncotarget 2018; 9: 11441-11450.","DOI":"10.18632\/oncotarget.23571"},{"key":"ref-1687911","unstructured":"Stenzel A, \u017buryn A, Grzanka AA, Grzanka A. Cykliny jako markery chor\u00f3b nowotworowych. J Oncol 2012; 62: 115-122."},{"key":"ref-1687912","doi-asserted-by":"crossref","unstructured":"Tan CB, Dhyan R, Sumreen M, Ahmed S,\u00a0Freedman L,\u00a0Mustacchia P. Pathologic rupture of\u00a0the\u00a0spleen in mantle-cell-type non-Hodgkin\u2019s lymphoma. Case Rep Med 2012; 2012: 351275.","DOI":"10.1155\/2012\/351275"},{"key":"ref-1687913","doi-asserted-by":"crossref","unstructured":"Tondini C, Zanini M, Lombardi F, Bengala C,\u00a0Rocca A,\u00a0Giardini R, et al. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I\u00a0or II histologically aggressive non-Hodgkin\u2019s lymphomas. J Clin Onkol 1993; 11: 720-725.","DOI":"10.1200\/JCO.1993.11.4.720"},{"key":"ref-1687914","unstructured":"National Cancer Institute at the\u00a0National Institute of\u00a0health. Available from :https:\/\/www.cancer.gov\/types\/lymphoma\/patient\/adult-nhl-treatment-pdq#top (accessed: 09.09.2024)."},{"key":"ref-1687915","doi-asserted-by":"crossref","unstructured":"Delarue R, Haioun C, Ribrag V, Brice P,\u00a0Delmer A,\u00a0Tilly H,  et al. CHOP and DHAP plus rituximab followed by\u00a0autologous stem cell transplantation in mantle cell lymphoma: a\u00a0phase 2 study from the\u00a0Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. Blood 2013; 121: 48-53.","DOI":"10.1182\/blood-2011-09-370320"},{"key":"ref-1687916","doi-asserted-by":"crossref","unstructured":"Eskelund CW, Kolstad A, Jerkeman M, R\u00e4ty R,\u00a0Laurell A,\u00a0Eloranta S, et al. 15-year follow-up of\u00a0the\u00a0second nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol 2016; 175: 410-418.","DOI":"10.1111\/bjh.14241"},{"key":"ref-1687917","doi-asserted-by":"crossref","unstructured":"Geisler CH, Kolstad A, Laurell A, Andersen NS,\u00a0Pedersen LB, Jerkeman M, et al. Long-term progression-free survival of\u00a0mantle cell lymphoma after intensive front-line immunochemotherapy with\u00a0in\u00a0vivo \u2013 purged stem cell rescue: a\u00a0nonrandomized phase 2 multicenter study by\u00a0the\u00a0Nordic Lymphoma Group. Blood 2008; 112: 2687-2693.","DOI":"10.1182\/blood-2008-03-147025"},{"key":"ref-1687918","doi-asserted-by":"crossref","unstructured":"Hermine O, Hoster E, Walewski J, Bosly A,\u00a0Stilgenbauer S, Thieblemont C,\u00a0et al. Addition of\u00a0high-dose cytarabine to\u00a0immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a\u00a0randomised, open-label, phase 3 trial of\u00a0the\u00a0European Mantle Cell Lymphoma Network. Lancet 2016; 388: 565-575.","DOI":"10.1016\/S0140-6736(16)00739-X"},{"key":"ref-1687919","doi-asserted-by":"crossref","unstructured":"Graf SA, Stevenson PA, Holmberg LA, Till BG,\u00a0Press OW, Chauncey TR, et al. Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. Ann Oncol 2015; 26: 2323-2328.","DOI":"10.1093\/annonc\/mdv364"},{"key":"ref-1687920","doi-asserted-by":"crossref","unstructured":"Le Gouill S, Thieblemont C, Oberic L, Moreau A,\u00a0Bouabdallah K,\u00a0Dartigeas C, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med 2017; 377: 1250-1260.","DOI":"10.1056\/NEJMoa1701769"},{"key":"ref-1687921","doi-asserted-by":"crossref","unstructured":"Rule S. The\u00a0modern approach to mantle cell lymphoma. Hematol Oncol 2019; 1: 66-69.","DOI":"10.1002\/hon.2596"},{"key":"ref-1687922","doi-asserted-by":"crossref","unstructured":"Silkenstedt E, Dreyling M. Mantle cell lymphoma-advances in molecular biology, prognostication and treatment approaches. Hematol Oncol 2021; 1: 31-38.","DOI":"10.1002\/hon.2860"},{"key":"ref-1687923","doi-asserted-by":"crossref","unstructured":"Rubin LG, Schaffner W. Clinical practice. Care of\u00a0the\u00a0asplenic patient. N Engl J Med 2014; 371: 349-356.","DOI":"10.1056\/NEJMcp1314291"}],"container-title":["Polish Journal of Pathology"],"original-title":["Spontaniczne patologiczne p\u0119kni\u0119cie \u015bledziony jako pierwszy objaw ch\u0142oniaka z kom\u00f3rek p\u0142aszcza - opis przypadku i przegl\u0105d literatury."],"link":[{"URL":"https:\/\/www.polishjournalofpathology.com\/pdf-210205-136510","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.polishjournalofpathology.com\/pdf-210205-136510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:18:04Z","timestamp":1782213484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.polishjournalofpathology.com\/Spontaneous-pathological-splenic-rupture-as-a-first-manifestation-of-mantle-cell,210205,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"alternative-id":["210205"],"URL":"https:\/\/doi.org\/10.5114\/pjp.2025.156558","relation":{},"ISSN":["1233-9687","2084-9869"],"issn-type":[{"value":"1233-9687","type":"print"},{"value":"2084-9869","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]}}}